Identification of a set of genes potentially responsible for resistance to ferroptosis in lung adenocarcinoma cancer stem cells.
Ferroptosis
/ genetics
Humans
Neoplastic Stem Cells
/ metabolism
Adenocarcinoma of Lung
/ genetics
Lung Neoplasms
/ genetics
Spheroids, Cellular
/ metabolism
Cell Line, Tumor
Lipid Peroxidation
Reactive Oxygen Species
/ metabolism
Gene Expression Regulation, Neoplastic
Drug Resistance, Neoplasm
/ genetics
Iron
/ metabolism
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
14
12
2023
accepted:
10
04
2024
revised:
29
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
epublish
Résumé
Scientific literature supports the evidence that cancer stem cells (CSCs) retain inside low reactive oxygen species (ROS) levels and are, therefore, less susceptible to cell death, including ferroptosis, a type of cell death dependent on iron-driven lipid peroxidation. A collection of lung adenocarcinoma (LUAD) primary cell lines derived from malignant pleural effusions (MPEs) of patients was used to obtain 3D spheroids enriched for stem-like properties. We observed that the ferroptosis inducer RSL3 triggered lipid peroxidation and cell death in LUAD cells when grown in 2D conditions; however, when grown in 3D conditions, all cell lines underwent a phenotypic switch, exhibiting substantial resistance to RSL3 and, therefore, protection against ferroptotic cell death. Interestingly, this phenomenon was reversed by disrupting 3D cells and growing them back in adherence, supporting the idea of CSCs plasticity, which holds that cancer cells have the dynamic ability to transition between a CSC state and a non-CSC state. Molecular analyses showed that ferroptosis resistance in 3D spheroids correlated with an increased expression of antioxidant genes and high levels of proteins involved in iron storage and export, indicating protection against oxidative stress and low availability of iron for the initiation of ferroptosis. Moreover, transcriptomic analyses highlighted a novel subset of genes commonly modulated in 3D spheroids and potentially capable of driving ferroptosis protection in LUAD-CSCs, thus allowing to better understand the mechanisms of CSC-mediated drug resistance in tumors.
Identifiants
pubmed: 38684666
doi: 10.1038/s41419-024-06667-w
pii: 10.1038/s41419-024-06667-w
doi:
Substances chimiques
Reactive Oxygen Species
0
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
303Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG24451
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG19865
Organisme : Sapienza Università di Roma (Sapienza University of Rome)
ID : RG123188B3C9EC04
Informations de copyright
© 2024. The Author(s).
Références
Cells. 2021 Nov 02;10(11):
pubmed: 34831207
Stem Cells Int. 2017;2017:1656053
pubmed: 28883835
Nat Rev Mol Cell Biol. 2024 Feb;25(2):133-155
pubmed: 37783783
Mol Med. 2023 Feb 6;29(1):20
pubmed: 36747131
Pharmacol Res. 2022 Mar;177:106013
pubmed: 34856333
Oxid Med Cell Longev. 2022 Jul 21;2022:2405943
pubmed: 35910848
Cell Death Dis. 2013 Dec 05;4:e947
pubmed: 24309934
Oncogene. 2018 May;37(18):2367-2378
pubmed: 29445137
Int J Mol Sci. 2022 Nov 30;23(23):
pubmed: 36499368
Stem Cells. 2020 Jan;38(1):6-14
pubmed: 31648395
Mol Cancer. 2022 Feb 12;21(1):47
pubmed: 35151318
Front Mol Biosci. 2022 May 12;9:901565
pubmed: 35647032
Redox Biol. 2021 Jul;43:102006
pubmed: 34030117
Cell Death Dis. 2023 Aug 14;14(8):519
pubmed: 37580393
Cancer Res. 2019 Oct 15;79(20):5355-5366
pubmed: 31270077
J Immunother Cancer. 2022 May;10(5):
pubmed: 35584864
J Exp Clin Cancer Res. 2021 Aug 24;40(1):265
pubmed: 34429143
Nat Chem Biol. 2017 Jan;13(1):91-98
pubmed: 27842070
Cell Death Dis. 2018 Aug 30;9(9):896
pubmed: 30166520
Br J Cancer. 2002 Jun 17;86(12):1884-7
pubmed: 12085180
Cell Rep. 2020 Dec 1;33(9):108444
pubmed: 33264619
Nat Rev Clin Oncol. 2023 Sep;20(9):624-639
pubmed: 37479810
FEBS Lett. 2002 Apr 24;517(1-3):225-8
pubmed: 12062442
J Cell Physiol. 2020 Mar;235(3):1877-1887
pubmed: 31397494
Eur J Cell Biol. 2023 Jun;102(2):151321
pubmed: 37137199
Arch Med Res. 2022 Dec;53(8):770-784
pubmed: 36462951
Biochem Biophys Rep. 2021 Jul 19;27:101074
pubmed: 34345719
Free Radic Biol Med. 2019 Mar;133:144-152
pubmed: 30219704
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
J Exp Clin Cancer Res. 2023 Mar 22;42(1):69
pubmed: 36945054
Trends Cell Biol. 2022 Sep;32(9):729-732
pubmed: 35701310
Adv Exp Med Biol. 2021;1301:25-40
pubmed: 34370286
J Biol Chem. 2022 Mar;298(3):101703
pubmed: 35148992
Mol Cell. 2020 Dec 3;80(5):828-844.e6
pubmed: 33128871
Cancer Lett. 2017 Oct 10;406:93-104
pubmed: 28797843
PLoS One. 2011;6(7):e21320
pubmed: 21789168
Int J Mol Sci. 2021 Jun 18;22(12):
pubmed: 34207342
Immunol Lett. 2018 Apr;196:22-32
pubmed: 29366662
Oxid Med Cell Longev. 2021 Sep 25;2021:8457521
pubmed: 34616505
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970